Company Profile
Mineralys Therapeutics Stock Price, News & Analysis
- Ticker:
- MLYS
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
27.33 USD (-0.18%)
Close
Last updated: August 11, 2026
2.38B USD
Market cap
Why the stock is moving
The latest monitored company update is “Mineralys Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update.” The corresponding closing-price reaction is not yet available.
Company overview
Aldosterone-Driven Disease
Mineralys Therapeutics develops medicines for hypertension and related conditions driven by dysregulated aldosterone.
Lorundrostat
Lorundrostat is an oral, selective aldosterone-synthase inhibitor under FDA review as an add-on treatment for adults with uncontrolled or resistant hypertension.
Registrational Evidence
The application is supported by five clinical studies, including the Phase 3 Launch-HTN and Phase 2 Advance-HTN trials. The Transform-HTN extension continues to collect longer-term safety and efficacy data.
Broader Aldosterone Opportunity
Mineralys views excessive aldosterone production as a contributor to cardiovascular and renal disease beyond hypertension, including chronic kidney disease and obstructive sleep apnea.
Future catalysts
- FDA action on the lorundrostat NDA by the December 22, 2026 PDUFA target date, with a potential commercial launch following approval.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Mineralys Therapeutics (MLYS)?
Mineralys Therapeutics (MLYS) most recently closed at 27.33 USD, a -0.18% move versus the previous session.
What is the market cap of Mineralys Therapeutics (MLYS)?
Mineralys Therapeutics currently has a market capitalization of 2.38B USD on BioPharmSignal.
What does Mineralys Therapeutics do?
Aldosterone-Driven Disease Mineralys Therapeutics develops medicines for hypertension and related conditions driven by dysregulated aldosterone. Lorundrostat Lorundrostat is an oral, selective aldosterone-synthase inhibitor under FDA review as an add-on treatment for adults with uncontrolled or resistant hypertension. Registrational Evidence The application...
On which exchange is MLYS stock listed?
Mineralys Therapeutics (MLYS) is associated with NASDAQ, United States, Biopharma.
What is lorundrostat?
FDA action on the lorundrostat NDA by the December 22, 2026 PDUFA target date, with a potential commercial launch following approval.
Which conditions is Mineralys Therapeutics targeting with lorundrostat?
Mineralys Therapeutics is associated with cardiovascular disease based on its company overview and current catalyst commentary.
How does Mineralys Therapeutics describe recent progress with lorundrostat?
FDA action on the lorundrostat NDA by the December 22, 2026 PDUFA target date, with a potential commercial launch following approval.
What is Aldosterone-Driven?
Aldosterone-Driven Disease Mineralys Therapeutics develops medicines for hypertension and related conditions driven by dysregulated aldosterone.